Participated · Series E · Sep 2021

Elligo Health Research provides a technology platform to accelerate clinical trials through direct access to known, diverse patients. The company leverages EHR data and its proprietary IntElligo technology to connect networks of hospitals and research sites. Its PatientSelect model engages networks to bring more patients clinical research as a care option, while SiteSelect and Research Partner Services enable sites to participate in trials. Elligo reports access to patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. The company intends to use loan proceeds for general growth and working capital. Elligo is led by founder and CEO John Potthoff, Ph.D., and is backed by investors including Morgan Stanley, Ally Bridge Group, Norwest Venture Partners, Piper Sandler, Noro-Moseley Partners and Hatteras Venture Partners. Elligo Health Research is a tech-powered, healthcare-enabling research organization based in Austin, TX, led by CEO John Potthoff. Its core product is the IntElligo Research Stack, which leverages electronic health records and the trusted patient–physician relationship to connect patients to clinical research as a care option. The company directly engages physicians and patients and combines proprietary data, technology, and services to support traditional, hybrid, and direct-to-patient trial designs. Elligo’s platform aims to accelerate development of pharmaceutical, biotechnology, medical device, and diagnostic products while expanding patient access to client trials. The company raised $135M in a Series E financing and plans to use the proceeds to acquire ClinEdge and further invest in its technology and data platform. Its solutions target challenges faced by pharma and biotech companies, contract research organizations, and research sites. Elligo Health Research is an integrated research organization (IRO) that accelerates development of pharmaceutical, biotechnology, medical device, and diagnostic products using its IntElligo Research Stack clinical technology and Goes Direct® approach. The company unites clinical experts with research infrastructure and leverages electronic health records to expand trial access while maintaining trusted patient-physician relationships. Elligo aims to drive clinical trial efficiency and expand participation among physicians and patients who otherwise would not participate in trials. The company reports more than 62 active research sites. Management says continued investor support has allowed rapid expansion of its physician and patient base. Financially, Elligo recently raised $20 million in a Series C financing led by Piper Jaffray Merchant Banking; this follows a $16 million Series B announced in March 2018. Elligo Health Research offers a platform that brings clinical research to the clinic, using electronic health records and other health data to identify real‑world patients and physicians for clinical studies. The company supplies personnel, procedures, technology and infrastructure so physicians can run research while keeping patients under their regular care. Elligo says it engages the 97 percent of physicians not currently offering clinical research to their patients. Management plans to expand services, grow its network of physician sites, and refine its technology platform to improve study efficiency and streamline data collection and submission. The company frames its mission as accelerating development of new pharmaceutical, biotech and medical device products by making research more accessible to physicians and patients. Recent financing will support expansion and technology refinement.